Nat Cardiovasc Res March 2025 PMID 39948308

Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin.

Ken-Ichi Hirano, Satomi Okamura, Koichiro Sugimura, Hideyuki Miyauchi, Yusuke Nakano, Kotaro Nochioka, Chikako Hashimoto, Yoshitaka Iwanaga, Kenichi Nakajima, Satoshi Yamaguchi, Yoko Yasui, Shinsaku Shimamoto, Makito Hirano, Mana Okune, Yuki Nishimura

Full text PDF Download social card

Mentions

Peak: 6 in Feb 2025

across 6 sources since Feb 2025

Extended reach

1,228

potential audience

Total likes

Video views

435

Mentions per month

Feb 2025 – Mar 2025

Where it's discussed

News16 articles
X / Twitter4 posts
Blogs3 articles
YouTube2 videos
Facebook2 posts
Bluesky1 posts

AI synopsis

What people are saying

Examples like mentions of 'tricaprin shows promise' and comments on its role in 'improving long-term survival' reveal a focus on therapeutic relevance and potential clinical impact. The tone is optimistic yet straightforward, emphasizing the significance of lipid metabolism in heart disease and highlighting the publication as an important development in cardiovascular research.

AgreementModerate agreement

Most discussions acknowledge the potential of tricaprin for improving heart failure outcomes related to TGCV, showing general agreement with the article's findings.

InterestModerate interest

Participants express moderate interest, particularly in the promising treatment and its implications, though some comments are more informational than inquisitive.

EngagementModerate engagement

Posts demonstrate moderate engagement through repetition of key concepts like 'lipid buildup' and 'long-term survival,' reflecting an understanding and sharing of core ideas.

ImpactModerate impact

The discussions suggest that readers see relevance for future therapy developments in heart failure management, indicating a recognition of the study's potential influence.

Abstract in brief

Heart disease, particularly triglyceride deposit cardiomyovasculopathy (TGCV), poses a global health threat, especially impacting adults through heart failure and high mortality rates.
TGCV is characterized by improper breakdown of long-chain triglycerides, causing energy failure in heart cells and associated complications like coronary artery disease and arrhythmias.
Research indicates that tricaprin, a type of medium-chain triglyceride, has shown promise in improving heart function and survival rates in TGCV patients, suggesting a need for further exploration across different populations.

Read the full abstract

All mentions

Tricaprin's Potential in Improving Heart Failure Outcomes in TGCV Patients

This study explored the potential benefits of tricaprin, a natural supplement, for individuals with triglyceride deposit cardiomyovasculopathy, a specific heart failure form caused by improper triglyceride breakdown…

VHFILM · Feb 23, 2025 285 views

Potential of Tricaprin for Improving Survival in Heart Failure Patients

This study explored the potential benefits of tricaprin, a natural supplement, for individuals with triglyceride deposit cardiomyovasculopathy which impacts heart function and survival. Results suggest significant…

VHFILM · Feb 14, 2025 150 views

George Oliver

@DrGroliver · X

Here's a new one. triglyceride deposit cardiomyovasculopathy. https://t.co/QYmXHmRRso #didntlearninmedschool

Mar 7, 2025 · 36 followers View post →

Shicheng Guo

@shihcheng.bsky.social · Bluesky

Feb 24, 2025 · 11 likes · 1 share View post →

Ralph Turchiano

@RalphTurchiano · X

Hope for Heart Failure: New Research on Tricaprin Ep. 1229 FEB 2025 https://t.co/h4odxyfkD7 via @YouTube

Feb 23, 2025 · 128 followers View post →

Shicheng Guo

@ShihchengGuo · X

Feb 18, 2025 · 499 followers View post →